or Try an Advanced Search...

    Technical Analysis for BDTX - Black Diamond Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 4.70 0.86% 0.04
    BDTX closed up 0.86 percent on Monday, July 1, 2024, on 79 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical BDTX trend table...
    Date Alert Name Type % Chg
    Hammer Candlestick Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.86%
    Volume Surge Other 0.86%
    Wide Bands Range Expansion 0.86%
    Oversold Stochastic Weakness 0.86%
    Pocket Pivot Bullish Swing Setup 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Older End-of-Day Signals for BDTX ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 4 hours ago
    60 Minute Opening Range Breakdown about 8 hours ago
    Down 3% about 10 hours ago
    Non-ADX 1,2,3,4 Bearish Retracement Entry about 10 hours ago
    Fell Below Previous Day's Low about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    BDTX Chart by TradingView
    Basic chart:

    Profile

    Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Cancer Treatment Enzymes Diamond Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Genetic Diseases Oncogenes Therapies For Cancer Protein Kinase Rare Genetic Disease Rare Genetic Diseases Black Diamond Kinase

    Is BDTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 30 Is Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock to Buy Right Now?
    Jun 27 Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive
    Jun 1 Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    May 29 Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
    May 22 Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) is favoured by institutional owners who hold 60% of the company
    May 10 Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?
    May 9 Black Diamond Therapeutics GAAP EPS of -$0.35 beats by $0.08
    May 9 Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    Apr 24 Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    Apr 15 Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?
    See more BDTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 7.66
    52 Week Low 1.62
    Average Volume 841,071
    200-Day Moving Average 3.88
    50-Day Moving Average 5.40
    20-Day Moving Average 5.13
    10-Day Moving Average 4.89
    Average True Range 0.38
    RSI (14) 40.83
    ADX 15.61
    +DI 20.34
    -DI 25.24
    Chandelier Exit (Long, 3 ATRs) 5.26
    Chandelier Exit (Short, 3 ATRs) 5.56
    Upper Bollinger Bands 6.22
    Lower Bollinger Band 4.03
    Percent B (%b) 0.3
    BandWidth 42.65
    MACD Line -0.17
    MACD Signal Line -0.10
    MACD Histogram -0.0705
    Fundamentals Value
    Market Cap 242.69 Million
    Num Shares 51.6 Million
    EPS -2.13
    Price-to-Earnings (P/E) Ratio -2.21
    Price-to-Sales 0.00
    Price-to-Book 1.63
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 5.11
    Resistance 3 (R3) 5.07 4.91 5.04
    Resistance 2 (R2) 4.91 4.80 4.92 5.01
    Resistance 1 (R1) 4.80 4.74 4.86 4.84 4.99
    Pivot Point 4.64 4.64 4.66 4.65 4.64
    Support 1 (S1) 4.53 4.53 4.59 4.57 4.41
    Support 2 (S2) 4.37 4.47 4.38 4.39
    Support 3 (S3) 4.26 4.37 4.36
    Support 4 (S4) 4.30